Astrazeneca (AZN) Short-Term Debt issuances (2009 - 2026)

Astrazeneca has reported Short-Term Debt issuances for 17 years, with the latest figure at -$19.0 million in Q2 2026.

• On a quarterly basis, Short-Term Debt issuances fell 102.99% year-over-year to -$19.0 million in Q2 2026; TTM through Jun 2026 was $945.0 million, a 218.12% increase from a year earlier, with the FY2025 full-year figure at $364.0 million, up 1274.19% from the prior year.
• Short-Term Debt issuances was -$19.0 million for Q2 2026 at Astrazeneca, down from $2.3 billion in the prior quarter.
• The five-year high for Short-Term Debt issuances was $2.3 billion in Q1 2026, with the low at -$1.9 billion in Q3 2024.
• Average Short-Term Debt issuances over 5 years is $216.9 million, with a median of $56.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Short-Term Debt issuances slumped 266.67% in 2023, then jumped 6108.0% in 2024.
• Over 5 years, Short-Term Debt issuances stood at $15.0 million in 2022, then plunged by 266.67% to -$25.0 million in 2023, then plunged by 2312.0% to -$603.0 million in 2024, then sank by 68.82% to -$1.0 billion in 2025, then surged by 98.13% to -$19.0 million in 2026.
• The last three Short-Term Debt issuances figures came in at -$19.0 million (Q2 2026), $2.3 billion (Q1 2026), and -$1.0 billion (Q4 2025), per Business Quant data.